Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.00.

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 6th. JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Finally, Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th.

Insider Activity

In related news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the transaction, the insider now directly owns 21,717 shares of the company’s stock, valued at $370,926.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Scott T. Rottinghaus sold 5,375 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now owns 21,717 shares in the company, valued at approximately $370,926.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the completion of the sale, the insider now owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The disclosure for this sale can be found here. Insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after buying an additional 134,292 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 1.3% during the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after buying an additional 10,952 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock worth $958,000 after buying an additional 8,645 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 18,003 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Stock Down 2.5 %

Shares of ENTA stock opened at $11.00 on Tuesday. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $17.80. The company has a 50 day moving average of $13.08 and a 200-day moving average of $13.56. The firm has a market cap of $232.97 million, a P/E ratio of -1.76 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company had revenue of $17.97 million for the quarter, compared to analysts’ expectations of $17.44 million. During the same period in the prior year, the company posted ($1.27) EPS. Enanta Pharmaceuticals’s revenue was down 4.9% compared to the same quarter last year. As a group, equities analysts expect that Enanta Pharmaceuticals will post -5.3 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.